Gelesis Holdings Inc (GLS) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gelesis Holdings Inc   (GLS)

Gelesis Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Gelesis Holdings Inc in the second quarter 2023?
Due to the lack of equity, it was not possible to calculate Gelesis Holdings Inc 's return on equity (ROE) in its second quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -53 -58 -58 -16 -33
Return On Equity (TTM) - - - - -
GLS's Total Ranking # # # # #
Equity (TTM) in Millions -32 -27 -25 -4 5
Seq. Equity Change - - - - -49.21 %
Seq. Net Income Change - - - - -

Back to GLS Management Effectiveness >> GLS's 5 Years Annual ROE >> Compare GLS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





GLS Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020

Total Equity in Millions -25 -54 -41 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -58 -13 -15 0 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to GLS Management Effectiveness >> GLS's 5 Years Annual ROE >> Compare GLS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GLS's' Return on Equity at Yahoo Finance
GLS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GLS's Competitors
Subscribers only: Roe for Gelesis Holdings Inc 's Suppliers
Subscribers only: Return On Equity for GLS's Customers




Companies with similar Return On Equity at Jun 30 2023, within Healthcare Sector ROE
Therapeuticsmd Inc   341.13 %
Intercept Pharmaceuticals inc   248.75 %
Inhibitor Therapeutics Inc   232.75 %
Theravance Biopharma inc   220.85 %
Ir med Inc   218.43 %
Scynexis Inc   212.29 %
Protalix Biotherapeutics inc   199.41 %
Halozyme Therapeutics Inc   193.28 %
Tff Pharmaceuticals Inc  169.67 %
Waters Corporation  164.61 %
Amgen Inc   164.15 %
Omeros Corporation  140.34 %
Biomx Inc  127.82 %
Idexx Laboratories Inc  104.84 %
Davita Inc   74.49 %
Medpace Holdings Inc   72.88 %
Chimerix Inc   72.53 %
Dariohealth Corp   71.65 %
Voyager Therapeutics Inc   69.09 %
Vaso Corporation  63.88 %
Eli Lilly And Company  59.90 %
Kiniksa Pharmaceuticals International Plc  58.48 %
Abbvie Inc   58.42 %
Gyre Therapeutics Inc   56.24 %
Star Equity Holdings Inc   54.61 %
Opus Genetics Inc   54.45 %
Zoetis Inc   48.61 %

Date modified: 2026-09-08T15:11:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.